Large-cap Consumer Discretionary company Kenvue has moved -3.7% so far today on a volume of 17,167,743, compared to its average of 16,391,496. In contrast, the S&P 500 index moved 1.0%.
Kenvue trades -11.72% away from its average analyst target price of $22.09 per share. The 12 analysts following the stock have set target prices ranging from $18.0 to $25.04, and on average have given Kenvue a rating of hold.
Anyone interested in buying KVUE should be aware of the facts below:
-
Kenvue's current price is 52.5% above its Graham number of $12.79, which implies that at its current valuation it does not offer a margin of safety
-
Kenvue has moved -24.8% over the last year, and the S&P 500 logged a change of 24.5%
-
Based on its trailing earnings per share of 0.9, Kenvue has a trailing 12 month Price to Earnings (P/E) ratio of 21.7 while the S&P 500 average is 15.97
-
KVUE has a forward P/E ratio of 15.7 based on its forward 12 month price to earnings (EPS) of $1.24 per share
-
The company has a price to earnings growth (PEG) ratio of 9.92 — a number near or below 1 signifying that Kenvue is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.33 compared to its sector average of 4.24
-
Kenvue Inc. operates as a consumer health company worldwide.
-
Based in Skillman, the company has 22,000 full time employees and a market cap of $37.33 Billion. Kenvue currently returns an annual dividend yield of 2.0%.